Výsledky vyhledávání - "Ellen Q. Wang"

Akademický článek

Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody

Autor: Ellen Q. Wang, Nitin Kaila, David Plowchalk, Leonid Gibiansky, Carla Yunis, Kevin Sweeney

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 2013-2026 (2023)

Abstract We sought to characterize the population pharmacokinetic/pharmacodynamic (PK/PD) relationship of bococizumab (RN316/PF‐04950615), a humanized IgG2Δa monoclonal antibody that binds to secreted human proprotein convertase subtilisin kexin t

Externí odkaz: https://doaj.org/article/e3a4824c28c44089a735782ecf1a49fe

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1

Autor: Daniel I. Chasman, Craig L. Hyde, Franco Giulianini, Rebecca D. Danning, Ellen Q. Wang, Timothy Hickling, Paul M Ridker, A. Katrina Loomis

Publikováno v: Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)

Abstract In this largest to-date genetic analysis of anti-drug antibody (ADA) response to a therapeutic monoclonal antibody (MAb), genome-wide association was performed for five measures of ADA status among 8844 individuals randomized to bococizumab,

Externí odkaz: https://doaj.org/article/afd8cc690884476983e660666b839af1

Zobrazit plný text záznamu

Plný text ve formátu HTML

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

Autor: Sakambari Tripathy, Lisy Wang, Martin E. Dowty, Melissa O'Gorman, Ellen Q. Wang, Vu Le, Bimal Malhotra

Publikováno v: Journal of Clinical Pharmacology

Abrocitinib, an oral once-daily Janus kinase 1 selective inhibitor, is under development for the treatment of atopic dermatitis. This phase 1, nonrandomized, open-label, single-dose study (NCT03660241) investigated the effect of renal impairment on t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d41520b947779041e70ce4f24cfefd3
https://doi.org/10.1002/jcph.1858

Zobrazit plný text záznamu

Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy

Autor: Jeffrey Crawford, Roberto A. Calle, Susie M. Collins, Yan Weng, Shannon L. Lubaczewski, Clare Buckeridge, Ellen Q. Wang, Magdalena A. Harrington, Anil Tarachandani, Michelle I. Rossulek, James H. Revkin

Publikováno v: Cancer Research. 83:CT108-CT108

Background: Cachexia is common in patients with advanced cancer and has been associated with elevated serum growth/differentiation factor 15 (GDF-15) concentrations. This first-in-patient, phase 1b, study assessed the use of ponsegromab, a monoclonal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c7627f3e336a7d3fba4a14a9268c117c
https://doi.org/10.1158/1538-7445.am2023-ct108

Zobrazit plný text záznamu

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies

Autor: Jack F. Bukowski, Paul M. Ridker, Daniel Baltrukonis, Pamela F. Schwartz, Ellen Q. Wang, Carla Yunis, Charles L. Shear

Publikováno v: Biodrugs

Background Anti-drug antibodies (ADAs) to bococizumab were detected in > 40% of subjects in the SPIRE lipid-lowering trials. The risk of cross-reactivity between anti-bococizumab antibodies and other approved anti-proprotein convertase subtilisin/kex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d070683c42e383e9b93e29732618fe6
https://doi.org/10.1007/s40259-019-00375-0

Zobrazit plný text záznamu

Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

Autor: Ellen Q. Wang, Vu Le, Jennifer A. Winton, Sakambari Tripathy, Sangeeta Raje, Lisy Wang, Martin E. Dowty, Bimal K. Malhotra

Publikováno v: Journal of clinical pharmacology. 62(4)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b6c1d7f83e415dc4e403f8ffca89996
https://pubmed.ncbi.nlm.nih.gov/34637151

Zobrazit plný text záznamu

Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices

Autor: Anna Plotka, Khurshid Mridha, Beth Sullivan, Joanne Salageanu, Daniel Baltrukonis, Ellen Q. Wang, Robert Frederich

Publikováno v: Clinical Pharmacology in Drug Development. 8:40-48

The pharmacokinetics (PK) and pharmacodynamics (PD) of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, were compared following a single 150-mg subcutaneous dose administered to healthy subjects (n = 156-158/arm) via: (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80b9f3a965d04265e8cf962d022f8fde
https://doi.org/10.1002/cpdd.454

Zobrazit plný text záznamu

Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion

Autor: John D. Louie, Gloria L. Hwang, Nishita Kothary, Marnix G.E.H. Lam, Ellen Q Wang, William T. Kuo, M. Abdelmaksoud, Daniel Y. Sze, Lawrence V. Hofmann, Feng Duan

Publikováno v: Radiology, 278(2), 612. Radiological Society of North America Inc.

PURPOSE: To study the comparative short-term safety and efficacy of transcatheter arterial chemoembolization (TACE) with drug-eluting LC Beads loaded with doxorubicin (DEBDOX), doxorubicin-eluting QuadraSpheres (hqTACE), and conventional TACE using e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a6b54c056248d4b9c74a4714a4b9b46
https://doi.org/10.1148/radiol.2015141417

Zobrazit plný text záznamu

Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia

Autor: Anne B. Cropp, Ellen Q. Wang, Harold E. Bays, Nitin Kaila, John Vincent, William T. Duggan, Kevin Sweeney, Christie M. Ballantyne, Joel M. Neutel, David R. Plowchalk

Publikováno v: The American Journal of Cardiology. 115(9):1212-1221

Bococizumab is a humanized monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, which may be a potential therapeutic option for reducing low-density lipoprotein cholesterol (LDL-C) levels in patients with hypercholesterolemia. I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05adb2ca7207797f73df4c08ae3a325e

Zobrazit plný text záznamu

Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetine

Autor: Thomas I. F. H. Cremers, Marieke G. C. van der Hart, Ellen Q. Wang, Hans Rollema, Shibing Deng, Elaine E. Tseng, Todd Wisialowski, Anthony A. Fossa

Publikováno v: Toxicology and Applied Pharmacology, 264(3), 343-350. ACADEMIC PRESS INC ELSEVIER SCIENCE

Norepinephrine reuptake inhibitors (NRIs) acutely increase norepinephrine (NE) levels, but therapeutic antidepressant activity is only observed after weeks of treatment because central NE levels progressively increase during continued drug exposure.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a4632415b619093ddf1b196447e4b1
https://research.rug.nl/en/publications/8f4e0a36-9fa0-4beb-aa38-b2671ec267b4

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání